The financing supports phase 3 evaluation of SIDIPREV, a first-in-class, non-antibiotic therapy designed to prevent C difficile infections, a leading US health care–associated threat.
This week, expert insights highlighted progress in reducing C difficile with electronic hand hygiene monitoring, advancing HIV prevention with lenacapavir, updating COVID-19 vaccines for high-risk groups, and more.
C difficile remains a major healthcare-associated infection. Despite clear guidelines, hand hygiene compliance often falls short, creating gaps between policy and practice. A case study from a hospital showed that after implementing an electronic hand hygiene monitoring system with behavior prompts, compliance improved.
C difficile carriers faced a higher baseline risk for hospital-onset infection compared to noncarriers, and this risk was not significantly influenced by antibiotic use.